

### AMENDMENTS TO THE CLAIMS

This listing of the claims will replace all prior versions, and listings, of claims in the application.

### LISTING OF CLAIMS

#### **Claims 1-23 (Cancelled)**

**Claim 24 (Currently Amended):** A method for inhibiting an alloimmune response in a ~~patent~~ patient comprising the step of administering a therapeutically effective amount of a soluble 18KDa recombinant human CD40L consisting of amino acids 108 to 261 set forth in SEQ ID NO:1, ~~or a functional fragment thereof~~ containing the active binding site of CD40 and capable of binding thereto.

#### **Claim 25 (Cancelled)**

**Claim 26 (Previously Added):** The method of claim 24, wherein the alloimmune response is a human anti-HLA alloimmune response.

**Claim 27 (Currently Amended):** A method for inhibiting T Cell function in an alloimmune response in a ~~patent~~ patient, comprising the step of administering a therapeutically effective amount of a soluble 18KDa recombinant human CD40L consisting of amino acids 108 to 261 of sequence set forth in SEQ ID NO:1 ~~or a functional fragment thereof~~ containing the active binding site of CD40 and capable of binding thereto.

#### **Claim 28 (Cancelled)**

**Claim 29 (Currently Amended):** The method of claim ~~28~~ 27, wherein the alloimmune response is a human anti-HLA alloimmune response.

**Claim 30 (Previously Added):** The method of claim 27, for treating or preventing a disease selected from the group consisting of systemic lupus erythematosus (SLE), sjögren's syndrome, scleroderma myositis, Raynaud's syndrome, type 1 diabetes, arthritis and rheumatoid arthritis, inflammatory bowel disease, uveitis, myasthenia gravis, multiple sclerosis, idiopathic thrombocytopenic purpura and graft vs host disease as well as allergies which are dependent on T cells.

**Claims 31-33 (Cancelled)**

---